Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen(St James's University Hospital), Tadeusz Robak(Medical University of Lodz), Ann Janssens(Universitair Ziekenhuis Leuven), K Govind Babu(Kidwai Memorial Institute of Oncology), Janusz Kłoczko(Medical University of Białystok), Sebastian Grosicki(Medical University of Silesia), Michael Doubek(University Hospital Brno), Panagiotis Panagiotidis(National and Kapodistrian University of Athens), Eva Kimby(Karolinska University Hospital), Anna Schuh(Churchill Hospital), Andrew R. Pettitt(Royal Liverpool and Broadgreen University Hospital NHS Trust), Thomas E. Boyd(Virginia Mason Memorial), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Ira Gupta(GlaxoSmithKline (United States)), Oliver Wright(GlaxoSmithKline (United Kingdom)), Iestyn Dixon(GlaxoSmithKline (United Kingdom)), Jodi Carey(GlaxoSmithKline (United States)), Chai‐Ni Chang(Research Triangle Park Foundation), Steen Lisby(Genmab (Denmark)), Astrid McKeown(GlaxoSmithKline (United Kingdom)), Fritz Offner(Ghent University Hospital)
Cited by 339
Abstract
Related Papers
No related papers found
Powered by citation graph analysis